

Biomarker Identification and Tumor Classification in Cervical Cancer

An integrated approach of Methylation and Expression Analysis

Authored by: CHODREDA Team

Team Members



Chaima BenMohamed



Opeyemi De Campos




Reem Atawia




David Ojo

BACKGROUND

- Cervical cancer is the fourth most common cancer type and the fourth cause of cancer-related death among women (Bray et al., 2024).
- Despite advancements in screening and treatment, effective biomarkers for early diagnosis, prognosis, and treatment stratification remain limited.
- Integration of methylation and expression analysis will provide a more comprehensive view of the molecular mechanisms involved in cervical cancer pathogenesis.



METHOD



EXPECTED RESULTS

- Identify differentially methylated CpG sites and genes with altered methylation status in cervical cancer
- By combining methylation and expression data, we hope that this study will uncover novel biomarkers and key hub genes with high connectivity in cervical cancer.
- Functional enrichment analysis of these hub genes is expected to reveal critical biological processes, pathways, and molecular functions impacted in cervical cancer.

References

- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 74(3), 229–263. <https://doi.org/10.3322/caac.21834>
- Bedell, S. L., Goldstein, L. S., Goldstein, A. R., & Goldstein, A. T. (2020). Cervical Cancer Screening: Past, Present, and Future. *Sexual Medicine Reviews*, 8(1), 28–37. <https://doi.org/10.1016/j.sxmr.2019.09.005>

THANK YOU